Beryl Drugs Balance Sheet Health
Financial Health criteria checks 3/6
Beryl Drugs has a total shareholder equity of ₹93.0M and total debt of ₹45.3M, which brings its debt-to-equity ratio to 48.7%. Its total assets and total liabilities are ₹170.0M and ₹77.0M respectively. Beryl Drugs's EBIT is ₹11.0M making its interest coverage ratio 2. It has cash and short-term investments of ₹1.8M.
Key information
48.7%
Debt to equity ratio
₹45.31m
Debt
| Interest coverage ratio | 2x |
| Cash | ₹1.78m |
| Equity | ₹93.03m |
| Total liabilities | ₹76.98m |
| Total assets | ₹170.02m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 524606's short term assets (₹89.6M) exceed its short term liabilities (₹47.0M).
Long Term Liabilities: 524606's short term assets (₹89.6M) exceed its long term liabilities (₹30.0M).
Debt to Equity History and Analysis
Debt Level: 524606's net debt to equity ratio (46.8%) is considered high.
Reducing Debt: 524606's debt to equity ratio has increased from 47% to 48.7% over the past 5 years.
Debt Coverage: 524606's debt is well covered by operating cash flow (65.2%).
Interest Coverage: 524606's interest payments on its debt are not well covered by EBIT (2x coverage).